Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Scope Fluidics Spolka Akcyjna's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -468.82%.
The historical rank and industry rank for Scope Fluidics Spolka Akcyjna's ROC (Joel Greenblatt) % or its related term are showing as below:
WAR:SCP'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1319.37 Med: -454.6 Max: 5341.11
Current: -459.86
During the past 10 years, Scope Fluidics Spolka Akcyjna's highest ROC (Joel Greenblatt) % was 5341.11%. The lowest was -1319.37%. And the median was -454.60%.
WAR:SCP's ROC (Joel Greenblatt) % is ranked worse than 83.41% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.02
vs WAR:SCP: -459.86
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SCP vs TMO, DHR, IDXX: ROC (Joel Greenblatt) % Comparison
For the Diagnostics & Research subindustry, Scope Fluidics Spolka Akcyjna's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scope Fluidics Spolka Akcyjna ROC (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Scope Fluidics Spolka Akcyjna's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Scope Fluidics Spolka Akcyjna's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -468.82% mean?
Scope Fluidics Spolka Akcyjna (WAR:SCP) has a ROC (Joel Greenblatt) % of -468.82% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Scope Fluidics Spolka Akcyjna and its competitors. According to the industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #176 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 83.4%.
Is Scope Fluidics Spolka Akcyjna's ROC (Joel Greenblatt) % too high?
Scope Fluidics Spolka Akcyjna's current ROC (Joel Greenblatt) % is -468.82%. Based on the distribution chart, Scope Fluidics Spolka Akcyjna ranks #176 out of 211 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Scope Fluidics Spolka Akcyjna has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scope Fluidics Spolka Akcyjna's ROC (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #176 out of 211 companies for ROC (Joel Greenblatt) %. This places Scope Fluidics Spolka Akcyjna in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good ROC (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Scope Fluidics Spolka Akcyjna and its competitors. Scope Fluidics Spolka Akcyjna's current ROC (Joel Greenblatt) % is -468.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scope Fluidics Spolka Akcyjna stock overvalued right now?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna (WAR:SCP) is currently considered Fairly Valued. The stock's GF Value™ is zł128.63, compared to a current price of zł120.00 — trading 6.7% below its estimated fair value. The current ROC (Joel Greenblatt) % is -468.82%. Scope Fluidics Spolka Akcyjna's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Scope Fluidics Spolka Akcyjna (WAR:SCP), the current ROC (Joel Greenblatt) % is -468.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scope Fluidics Spolka Akcyjna (WAR:SCP) Overvalued in 2026?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna stock appears to be undervalued.
The current stock price of zł120.00 is trading 6.7% below its estimated GF Value™ of zł128.63.
GuruFocus considers Scope Fluidics Spolka Akcyjna to be Fairly Valued.
Key valuation signals for WAR:SCP:
ROC (Joel Greenblatt) %: -468.82%
GF Value™: zł128.63 vs. price of zł120.00 (6.7% below fair value)
No single metric tells the full story. See the WAR:SCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scope Fluidics Spolka Akcyjna Business Description
Scope Fluidics Spolka Akcyjna focuses on global challenges in health to develop diagnostic and med tech solutions. The company combines the expertise in microfluidic technology with the awareness of the challenges in medical diagnostics. It provides prototyping support for diagnostic services.
50GF Score
Get the complete analysis for WAR:SCP
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCP has been successfully added to your 
